TVM Capital

Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Definiens is a company that specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. Its software offers detailed insights from whole tissue slides, cell-based assays, and full-body scans, enabling users to correlate this information with data from various sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating new knowledge, thereby enhancing decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, Definiens aims to advance research fields, contribute to the development of personalized medicine, and improve patient quality of life. The company also maintains offices across the United States.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Based in Waltham, Massachusetts, the company was founded in 2001 and has a strong emphasis on addressing the medical needs of these patient populations. Its lead product candidate, vonapanitase, is designed to improve hemodialysis vascular access outcomes and has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Additionally, the company is exploring vonapanitase in a Phase I clinical trial targeting peripheral artery disease. Proteon Therapeutics leverages a unique understanding of tissue remodeling to advance its pipeline of proprietary therapeutics, including another candidate aimed at enhancing blood flow following vascular surgery procedures.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

invendo medical aims to become a globally leading developer and distributor of disposable, highly flexible and easy-to-use endoscopy products in the field of gastroenterology. Innovation activity in gastroenterological endoscopy has in the past decades nearly exclusively focused on the improvement of optical capabilities. However, invendo medical´s goal is to improve patient compliance and thereby increase the number of procedures performed.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Definiens is a company that specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostic biomarkers, and healthcare sectors. Its software offers detailed insights from whole tissue slides, cell-based assays, and full-body scans, enabling users to correlate this information with data from various sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating new knowledge, thereby enhancing decision-making in research, diagnostics, and therapy. Headquartered in Munich, Germany, Definiens aims to advance research fields, contribute to the development of personalized medicine, and improve patient quality of life. The company also maintains offices across the United States.

Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

Vivoryon Therapeutics AG is a clinical-stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products aimed at treating Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has successfully completed Phase IIb clinical trials for Alzheimer's treatment. Additionally, Vivoryon is advancing PQ1565, another small molecule targeting cancer, and is developing a monoclonal antibody to enhance the clearance of toxic pyroglutamate-Abeta (pGlu-Abeta). The company has established research collaborations with University Medical Center Schleswig-Holstein, Nordic Bioscience, and the Fraunhofer Institute, focusing on cancer immunotherapy and the clinical development of its candidates. Founded in 1997 and originally named Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Based in Waltham, Massachusetts, the company was founded in 2001 and has a strong emphasis on addressing the medical needs of these patient populations. Its lead product candidate, vonapanitase, is designed to improve hemodialysis vascular access outcomes and has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Additionally, the company is exploring vonapanitase in a Phase I clinical trial targeting peripheral artery disease. Proteon Therapeutics leverages a unique understanding of tissue remodeling to advance its pipeline of proprietary therapeutics, including another candidate aimed at enhancing blood flow following vascular surgery procedures.

Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.

F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators to accelerate customers' return on investment.

Anchor Therapeutics, Inc., a discovery and pre-clinical development-stage biopharmaceutical company, develops pharmaceutical candidates to address cancer, inflammation, metabolism, heart disease, and pain. The company develops Pepducin lipopeptide drug candidates, which are molecules that target the intracellular domains of G protein coupled receptors (GPCRs) to allosterically modulate GPCR signaling. Its Pepducin technology platform is used to develop lipopeptide allosteric modulators for intractable GPCR targets. The company was formerly known as Ascent Therapeutics, Inc. and changed its name to Anchor Therapeutics, Inc. in March 2010. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

Helomics Corporation is a personalized healthcare company focused on oncology, providing innovative tools to assist physicians and patients in making informed decisions throughout the cancer care continuum. It has developed a Precision Cellular Analytical Platform that analyzes cellular data over a 25-35 day period. Among its key products are ChemoFx, which aids in selecting effective treatments for gynecologic cancer patients; BioSpeciFx, offering biomarker tests for evaluating tumor responses at the molecular level; and GeneFx products, which use gene signatures to inform treatment options for colon and lung cancer patients. Additionally, Helomics provides tumor profiling services, including bioinformatics and patient-derived tumor models, which enhance clinical research and drug development. The company employs artificial intelligence through its D-CHIP platform to create personalized oncology roadmaps for patients. Founded in 1995 and headquartered in Pittsburgh, Pennsylvania, Helomics operates as a subsidiary of Predictive Oncology Inc.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.

VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated network planning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.

Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.

Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.

F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

Arteris is a prominent provider of system IP that specializes in accelerating system-on-chip (SoC) development for various electronic systems. The company focuses on network-on-chip (NoC) interconnect technology and offers automation software for SoC integration, which enhances product performance while reducing power consumption and time to market. Arteris' solutions enable customers to efficiently implement NoC IP, along with providing ongoing support, maintenance, professional services, and training. With operations spanning the Americas, Asia Pacific, and Europe, the company derives a significant portion of its revenue from the Asia Pacific region, positioning itself as a key player in the semiconductor industry.

Vivoryon Therapeutics AG is a clinical-stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products aimed at treating Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has successfully completed Phase IIb clinical trials for Alzheimer's treatment. Additionally, Vivoryon is advancing PQ1565, another small molecule targeting cancer, and is developing a monoclonal antibody to enhance the clearance of toxic pyroglutamate-Abeta (pGlu-Abeta). The company has established research collaborations with University Medical Center Schleswig-Holstein, Nordic Bioscience, and the Fraunhofer Institute, focusing on cancer immunotherapy and the clinical development of its candidates. Founded in 1997 and originally named Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

Ubidyne, established in 2005, specializes in digital active antenna technology, specifically its innovative Antenna Embedded Radio™ system. This technology is designed to enhance mobile communication by integrating micro-radio technology directly within wireless antennas. Ubidyne's products, which are offered through collaboration with Nokia Siemens Networks, support a range of standards including GSM, UMTS, HSPA+, and LTE. The company's integrated active antenna systems are compatible with CPRI and OBSAI optical interfaces, allowing for advanced multi-standard wireless services that cater to various applications, from pico cells to large-scale macro cells and distributed in-building systems. By eliminating the need for coaxial feeder cables, remote electrical tilt, and additional amplifiers, Ubidyne's solutions significantly reduce energy consumption while improving radio performance, deployment flexibility, coverage, and capacity of mobile networks globally.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Based in Waltham, Massachusetts, the company was founded in 2001 and has a strong emphasis on addressing the medical needs of these patient populations. Its lead product candidate, vonapanitase, is designed to improve hemodialysis vascular access outcomes and has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Additionally, the company is exploring vonapanitase in a Phase I clinical trial targeting peripheral artery disease. Proteon Therapeutics leverages a unique understanding of tissue remodeling to advance its pipeline of proprietary therapeutics, including another candidate aimed at enhancing blood flow following vascular surgery procedures.

Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators to accelerate customers' return on investment.

ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.

ExtendMedia provides software and media services that enable content providers and distributors to quickly and securely create, deliver, manage & monetize online content offerings over many devices. Their flagship product, OpenCASE, is a trusted foundation on which providers are building their digital media businesses. ExtendMedia has over 16 years of experience working closely with the world's most successful and innovative communications and media companies. Their in-depth knowledge has been built into OpenCASE: an open architecture for integration with existing systems; features for skillful automation of even the largest content delivery systems to increase efficiency; and support for flexible business models.

Silicon Hive BV is a company that specializes in semiconductor intellectual property, providing a range of solutions including processor cores, program development tools, and application libraries. Founded in 2003 and based in Eindhoven, the Netherlands, with additional offices in San Jose, Tokyo, Seoul, and Bangalore, Silicon Hive designs, builds, and licenses application-specific systems primarily for semiconductor manufacturers and original equipment manufacturers. Its products enable the creation of programmable integrated circuits tailored for imaging, video, and wireless communication applications. The company's innovative solutions and parallel processor technologies are integral to the functionality of camera systems, video systems, and wireless communications, allowing clients in the consumer electronics sector to enhance their offerings. Silicon Hive has been operating independently since April 2007.

CommProve specializes in real-time Quality of Service (QoS) monitoring for wireless networks, having been established in 1996 by experts in network operations and software engineering. The company focuses on developing software that allows wireless operators to monitor and enhance their network performance and subscriber experience. Its platform facilitates real-time data acquisition and analysis, collecting information from both analogue and LTE mobile networks. By integrating this data with business rules and subscriber information, CommProve enables mobile network operators to gain insights into their operations, thereby improving financial performance and ensuring a high-quality user experience. The company's initial engagements with Tier 1 customers highlighted the necessity for effective measurement and reporting of subscriber experience through the radio link.

SpePharm is a European specialty pharmaceutical company focused on acquiring, registering, and marketing high-value medicines primarily for the hospital market. The company specializes in oncology, hematology, and supportive care, offering medical products that assist clinicians in managing oral complications associated with radiotherapy or chemotherapy. SpePharm's management team possesses extensive global experience in the pharmaceutical sector, particularly with a deep understanding of the European regulatory landscape and the nuances of niche and orphan products. Their expertise allows them to implement innovative strategies and achieve notable successes in the field.

Since its inception, BitWave has been dedicated to the development of a universal programmable transceiver, the Softransceiver RFIC. The technology will allow wireless carriers and cell phone manufacturers to deploy more services and devices in less time with additional functionality.

Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly

Arteris is a prominent provider of system IP that specializes in accelerating system-on-chip (SoC) development for various electronic systems. The company focuses on network-on-chip (NoC) interconnect technology and offers automation software for SoC integration, which enhances product performance while reducing power consumption and time to market. Arteris' solutions enable customers to efficiently implement NoC IP, along with providing ongoing support, maintenance, professional services, and training. With operations spanning the Americas, Asia Pacific, and Europe, the company derives a significant portion of its revenue from the Asia Pacific region, positioning itself as a key player in the semiconductor industry.

Winbox Technologies specializes in connected-TV solutions tailored for original equipment manufacturers and service providers. The company offers a range of hardware and software products designed to streamline the development of IPTV receivers, video-on-demand systems, hard disk video recorders, connected TVs, and set-top boxes. By utilizing Winbox Technologies' offerings, customers can reduce both development time and investment costs. The company provides complete "TurnKey" solutions that encompass hardware, software, and production services, as well as the option to license specific technology modules for in-house development. This enables clients to enhance their operational efficiency and accelerate time-to-market for their connected-TV products.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.

Albireo Pharma, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in the development and commercialization of novel bile acid modulators aimed at treating orphan pediatric liver diseases and gastrointestinal disorders. The company’s lead product candidate, odevixibat, is an ileal bile acid transporter (IBAT) inhibitor currently in phase III clinical trials for progressive familial intrahepatic cholestasis and other cholestatic liver diseases, including biliary atresia and Alagille syndrome. Additionally, Albireo is developing Elobixibat, which targets chronic constipation and nonalcoholic steatohepatitis, as well as A3384 for various gastrointestinal diseases. The company has also established a license agreement with EA Pharma for the development and commercialization of Elobixibat.

Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly

Enigma Semiconductor is developing next generation silicon solutions to enable the future of wired communications. Their solutions push the limits of technology to create compelling components and subsystems for applications such as Metropolitan and Access Networks, Enterprise and internet infrastructure and Storage Systems. Enigma is managed and stalled by a team of experienced professionals from established names like Cisco, intel and Vitesse Semiconductor.

Ascent Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, metabolic CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets.

Direvo Industrial Biotechnology GmbH, founded in 2008 and based in Cologne, Germany, specializes in developing and marketing biology-based products and processes for non-pharmaceutical industries. The company focuses on providing bio-based solutions in clean energy, clean chemistry, and biomass conversion markets by leveraging its expertise in enzymes and microbes. Its BluZy platform features technologies tailored for the grain ethanol industry, enhancing both the nutritional value of by-products and the efficiency of ethanol production processes. Additionally, the BluServ platform offers automated high-throughput screening for protein and strain engineering, while the BluCon technology facilitates the conversion of non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with major industry players and is privately owned, with investments from various equity partners and private investors.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Based in Waltham, Massachusetts, the company was founded in 2001 and has a strong emphasis on addressing the medical needs of these patient populations. Its lead product candidate, vonapanitase, is designed to improve hemodialysis vascular access outcomes and has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Additionally, the company is exploring vonapanitase in a Phase I clinical trial targeting peripheral artery disease. Proteon Therapeutics leverages a unique understanding of tissue remodeling to advance its pipeline of proprietary therapeutics, including another candidate aimed at enhancing blood flow following vascular surgery procedures.

Arteris is a prominent provider of system IP that specializes in accelerating system-on-chip (SoC) development for various electronic systems. The company focuses on network-on-chip (NoC) interconnect technology and offers automation software for SoC integration, which enhances product performance while reducing power consumption and time to market. Arteris' solutions enable customers to efficiently implement NoC IP, along with providing ongoing support, maintenance, professional services, and training. With operations spanning the Americas, Asia Pacific, and Europe, the company derives a significant portion of its revenue from the Asia Pacific region, positioning itself as a key player in the semiconductor industry.

Netviewer GmbH manufactures and provides Web conferencing solutions. Its products enable users to view and edit documents jointly over the Internet. The company provides Netviewer Meet that lets the client to use the Internet to hold meetings; and Netviewer Support for internal and external customers. Its Netviewer Meet has application in project collaborations, live demos, and training. The company also offers Netviewer Admin that performs administrative tasks without involving another person; Netviewer Present that has provides online meetings for participants; online education, training, and informational events; Webinars to promote sales and customer loyalty; and conventions over the Internet. It offers its products as software-as-a-service option. The company was founded in 2001 and is headquartered in Karlsruhe, Germany. It has subsidiary operations in Thalwil, Switzerland; Levallois-Perret, France; Surrey, the Great Britain; the United States; Amsterdam, the Netherlands; Wien, Austria; Milano, Italy; Spain; Poland; Scandinavia; Stockholm, Sweden; and Karlsruhe, Germany.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

Silicon Hive BV is a company that specializes in semiconductor intellectual property, providing a range of solutions including processor cores, program development tools, and application libraries. Founded in 2003 and based in Eindhoven, the Netherlands, with additional offices in San Jose, Tokyo, Seoul, and Bangalore, Silicon Hive designs, builds, and licenses application-specific systems primarily for semiconductor manufacturers and original equipment manufacturers. Its products enable the creation of programmable integrated circuits tailored for imaging, video, and wireless communication applications. The company's innovative solutions and parallel processor technologies are integral to the functionality of camera systems, video systems, and wireless communications, allowing clients in the consumer electronics sector to enhance their offerings. Silicon Hive has been operating independently since April 2007.

ExtendMedia provides software and media services that enable content providers and distributors to quickly and securely create, deliver, manage & monetize online content offerings over many devices. Their flagship product, OpenCASE, is a trusted foundation on which providers are building their digital media businesses. ExtendMedia has over 16 years of experience working closely with the world's most successful and innovative communications and media companies. Their in-depth knowledge has been built into OpenCASE: an open architecture for integration with existing systems; features for skillful automation of even the largest content delivery systems to increase efficiency; and support for flexible business models.

Azea Networks Limited, provides world-class submarine optical networking solutions Azea Networks provides world-class submarine optical networking solutions that allow operators to exploit the full potential of their existing cable assets. Azea is uniquely focused on delivering substantial, and cost effective, capacity gains over existing undersea systems. The Azea team combines extensive optical engineering experience in characterisation, system design, modelling and product implementation to provide technologies and services that are a compelling alternative to the cost and risk of deploying new submarine cable systems. Azea’s head office is in London, with manufacturing in Scotland and a number of regional support offices.

Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators to accelerate customers' return on investment.

Hymite is a venture funded product company bringing to market the next generation packaging platform for use with High Power (HP) / Ultra-high Brightness (UHB) LEDs. Hymite's Engineered Silicon (Si) package platform delivers new levels of performance and value to their customers developing products for Solid State Lighting applications.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. The company focuses on patients suffering from acute renal failure and additional indications where kidney function is compromised. It develops RBI-01, which utilizes physiologically active human renal epithelial cells and administered ex vivo, to replace and maintain severely compromised, or lost kidney functions due to illness, or trauma. The company was founded in 1995 as Nephros Therapeutics, Inc. and changed its name to RenaMed Biologics, Inc. in 2005. RenaMed Biologics, Inc. is based in Lincoln, Rhode Island.

Magen BioSciences is a biotechnology company based in Waltham, Massachusetts, focused on developing pharmaceutical products aimed at enhancing human skin health. Utilizing a science-driven approach, the company leverages its comprehensive understanding of both normal and diseased skin biology to create solutions that improve the health and appearance of the skin.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

CoreOptics is the leading providers of 10G and 40G Distortion Tolerant Transponder Modules and IC solutions for Metro, Regional and Long Haul optical & data networking markets.With a belief that optical communications networks must become open systems that economically transmit information regardless of data rate or fiber types, CoreOptics provides the only field-proven MLSE-based equalization solutions on the market today. This innovative technology helps Tier 1 systems vendors and carriers deploy the next generation of high-performance networks using their existing fiber infrastructure. CoreOptics' 10G and 40G Distortion Tolerant Transponder Modules eliminate the need for Optical Compensators and the respective Second Stage Amplifiers, allowing customers to reduce their first-in deployment cost by up to 30%.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Based in Waltham, Massachusetts, the company was founded in 2001 and has a strong emphasis on addressing the medical needs of these patient populations. Its lead product candidate, vonapanitase, is designed to improve hemodialysis vascular access outcomes and has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Additionally, the company is exploring vonapanitase in a Phase I clinical trial targeting peripheral artery disease. Proteon Therapeutics leverages a unique understanding of tissue remodeling to advance its pipeline of proprietary therapeutics, including another candidate aimed at enhancing blood flow following vascular surgery procedures.

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

Helomics Corporation is a personalized healthcare company focused on oncology, providing innovative tools to assist physicians and patients in making informed decisions throughout the cancer care continuum. It has developed a Precision Cellular Analytical Platform that analyzes cellular data over a 25-35 day period. Among its key products are ChemoFx, which aids in selecting effective treatments for gynecologic cancer patients; BioSpeciFx, offering biomarker tests for evaluating tumor responses at the molecular level; and GeneFx products, which use gene signatures to inform treatment options for colon and lung cancer patients. Additionally, Helomics provides tumor profiling services, including bioinformatics and patient-derived tumor models, which enhance clinical research and drug development. The company employs artificial intelligence through its D-CHIP platform to create personalized oncology roadmaps for patients. Founded in 1995 and headquartered in Pittsburgh, Pennsylvania, Helomics operates as a subsidiary of Predictive Oncology Inc.

Cambridge Broadband designs wireless back-haul and access provisions that improve telecommunication network capacity and efficiency under increasing mobile data growth. The company's wireless back-haul and access provisions offers carrier-class, point-to-multipurpose broadband wireless access equipment, enabling telecom and mobile operators to accelerate customers' return on investment.

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, trading symbol NWRN.

Impress Software Solutions, Inc. specializes in developing packaged integration applications that facilitate the integration of project management and geographical information systems with SAP. Its key products include Impress for EPM, which synchronizes project-related data between SAP PM/PS and platforms like Microsoft Project or Primavera, and Impress for GIS, which connects SAP assets with GIS features to maintain accurate asset information across systems. The company offers solutions for plant turnarounds, routine maintenance, information technology, capital projects, and spatial asset management. Its clientele spans various industries, including energy and utilities, oil and gas, aerospace and defense, chemicals, and engineering and construction. Founded in 1997 and headquartered in Waltham, Massachusetts, with additional offices in Hannover, Germany, and Huizerstraatweg, the Netherlands, Impress Software Solutions operates as a subsidiary of Impress Software GmbH and has established partnerships with notable organizations such as Accenture, ESRI, Microsoft, and Primavera.

Ubidyne, established in 2005, specializes in digital active antenna technology, specifically its innovative Antenna Embedded Radio™ system. This technology is designed to enhance mobile communication by integrating micro-radio technology directly within wireless antennas. Ubidyne's products, which are offered through collaboration with Nokia Siemens Networks, support a range of standards including GSM, UMTS, HSPA+, and LTE. The company's integrated active antenna systems are compatible with CPRI and OBSAI optical interfaces, allowing for advanced multi-standard wireless services that cater to various applications, from pico cells to large-scale macro cells and distributed in-building systems. By eliminating the need for coaxial feeder cables, remote electrical tilt, and additional amplifiers, Ubidyne's solutions significantly reduce energy consumption while improving radio performance, deployment flexibility, coverage, and capacity of mobile networks globally.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

WILEX a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II substance for the treatment of pancreatic and breast cancer. The company's products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated network planning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Aventeon, Inc. provides mobile enterprise software solutions. It develops software applications and middleware that are designed to streamline processes that connect mobile client device users with the back-end ERP systems of their organizations. The company offers applications for the functional areas of sales, service, and logistics, as well as various industry vertical applications, such as utility, transport and logistics, manufacturing, telecom, retail, pharmaceutical, and health care industry. Aventeon, Inc. was formerly known as Aventeon GmbH. The company was founded in 2000 and is based in Munich, Germany with additional offices in Seattle, Washington; Culemborg, the Netherlands; and Hyderabad, India.

VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated network planning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Impress Software Solutions, Inc. specializes in developing packaged integration applications that facilitate the integration of project management and geographical information systems with SAP. Its key products include Impress for EPM, which synchronizes project-related data between SAP PM/PS and platforms like Microsoft Project or Primavera, and Impress for GIS, which connects SAP assets with GIS features to maintain accurate asset information across systems. The company offers solutions for plant turnarounds, routine maintenance, information technology, capital projects, and spatial asset management. Its clientele spans various industries, including energy and utilities, oil and gas, aerospace and defense, chemicals, and engineering and construction. Founded in 1997 and headquartered in Waltham, Massachusetts, with additional offices in Hannover, Germany, and Huizerstraatweg, the Netherlands, Impress Software Solutions operates as a subsidiary of Impress Software GmbH and has established partnerships with notable organizations such as Accenture, ESRI, Microsoft, and Primavera.

Aventeon, Inc. provides mobile enterprise software solutions. It develops software applications and middleware that are designed to streamline processes that connect mobile client device users with the back-end ERP systems of their organizations. The company offers applications for the functional areas of sales, service, and logistics, as well as various industry vertical applications, such as utility, transport and logistics, manufacturing, telecom, retail, pharmaceutical, and health care industry. Aventeon, Inc. was formerly known as Aventeon GmbH. The company was founded in 2000 and is based in Munich, Germany with additional offices in Seattle, Washington; Culemborg, the Netherlands; and Hyderabad, India.

Enigma Semiconductor is developing next generation silicon solutions to enable the future of wired communications. Their solutions push the limits of technology to create compelling components and subsystems for applications such as Metropolitan and Access Networks, Enterprise and internet infrastructure and Storage Systems. Enigma is managed and stalled by a team of experienced professionals from established names like Cisco, intel and Vitesse Semiconductor.

Hymite is a venture funded product company bringing to market the next generation packaging platform for use with High Power (HP) / Ultra-high Brightness (UHB) LEDs. Hymite's Engineered Silicon (Si) package platform delivers new levels of performance and value to their customers developing products for Solid State Lighting applications.

TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.

Since its inception, BitWave has been dedicated to the development of a universal programmable transceiver, the Softransceiver RFIC. The technology will allow wireless carriers and cell phone manufacturers to deploy more services and devices in less time with additional functionality.

Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated network planning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.

Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Clearsight provides embedded application components for decision systems that return unparalleled answers, fast. Utilizing breakthrough mathematics, Clearsight components offer organizations a whole new level of answer—answers that incorporate new types of data and knowledge, assume a dynamic environment, and work in real time. CLARITY. Organizations need to trust that their decision systems deliver the right answers, based on the right information, at the right time. By harnessing a new form of mathematics that fuses data, process, and empirical knowledge, Clearsight systems return better, clearer answers that account for interdependencies and manage uncertainty. SPEED. Decision systems today are complex and costly to build. Through an innovative architecture, which separates the problem definition process from the execution engine, Clearsight application components dramatically increase the efficiency of building and executing powerful decision systems that work in real time. ADAPTABILITY. Keeping decision systems current can be costly and time consuming, but the unique hierarchical modeling structure of Clearsight eases the burden of maintenance. Because its application components are actually built for change, they learn and adapt to new environments, parameters, or inputs and shorten the cycle for changing models.

VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated network planning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia.

TissueInformatics.Inc™ is the only company providing Tissue Information Solutions™, a comprehensive, fully integrated set of tools to quickly and easily capture, analyze, search and mine the rich data present in tissue. Tissue Information Solutions create new knowledge and bring greater speed and accuracy for better decisions in scientific research and development. Each customizable Tissue Information Solution is based upon TissueInformatics' unique Quantf(x)™ technology platform. Quantf(x)™ is applied to automatically identify and quantify any feature ( f ) of interest in a customer-specified tissue investigation ( x ). Quantf(x)™ takes tissue information to the next power by replacing existing manual processes that are subjective and time-consuming. Archived, high-resolution images are linked with quantitative descriptions of tissue structure and function in a flexible data format for analysis and correlation with other biological data. TissueInformatics.Inc™ pioneered "tissue informatics," the segment of bioinformatics focused on tissue information. Tissue information is comprised of the components and organizational patterns of tissue features – human, plant or animal – that can be made visible, objectively analyzed and recorded.

Helomics Corporation is a personalized healthcare company focused on oncology, providing innovative tools to assist physicians and patients in making informed decisions throughout the cancer care continuum. It has developed a Precision Cellular Analytical Platform that analyzes cellular data over a 25-35 day period. Among its key products are ChemoFx, which aids in selecting effective treatments for gynecologic cancer patients; BioSpeciFx, offering biomarker tests for evaluating tumor responses at the molecular level; and GeneFx products, which use gene signatures to inform treatment options for colon and lung cancer patients. Additionally, Helomics provides tumor profiling services, including bioinformatics and patient-derived tumor models, which enhance clinical research and drug development. The company employs artificial intelligence through its D-CHIP platform to create personalized oncology roadmaps for patients. Founded in 1995 and headquartered in Pittsburgh, Pennsylvania, Helomics operates as a subsidiary of Predictive Oncology Inc.

Interactive Silicon is a technology-based, intellectual property company that is turning LOTS of heads with its breakthrough memory technology.

Morphics Technology, Inc. specializes in communications systems, focusing on the development of Wireless Signal Processors (WSPs) and Intellectual Property (IP) Cores for wireless infrastructure and terminal products. The company combines its knowledge in communications theory, digital signal processing, computer architecture, and silicon engineering to provide high-performance signal processing solutions that are both cost-effective and scalable for next-generation wireless networks. Morphics' off-the-shelf WSPs are designed to meet the cost-reduction demands of 3G basestation manufacturers by delivering efficient baseband processing with high channel density. These programmable processors allow equipment vendors to integrate proprietary radio-link and network performance features while supporting various leading 3G wireless standards.

TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.

PolyTrax Information Technology AG is a logistics and supply chain company based out of 3 Danziger Straße, RO, BY, Germany.

eCustomers, Inc. is revolutionizing the way consumers interact with businesses online. To empower consumers, eCustomers, Inc. was created to be a pioneer and leading Internet-based infomediary that delivers valuable personalized content to eBusiness systems.